IL-1β, IL-6 and TNF gene polymorphisms do not affect the treatment outcome of rheumatoid arthritis patients with leflunomide

Pharmacological Reports

Volumn 61, Issue 2, 2009, Pages 281-287

  Pawlik, Andrzej ^a   Herczyńska, Magdalena ^b   Kurzawski, Mateusz ^a   Safranow, Krzysztof ^a   Dziedziejko, Violetta ^a   Juzyszyn, Zygmunt ^a   Droździk, Marek ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Department of General and Transplantation Surgery   (Poland)

Author keywords

Cytokines; Leflunomide; Polymorphism; Rheumatoid arthritis

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEFLUNOMIDE; TUMOR NECROSIS FACTOR; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; ENZYME ACTIVITY; ERYTHROCYTE COUNT; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; THROMBOCYTE; TREATMENT OUTCOME; AGED; GENETICS; MIDDLE AGED;

ADULT; AGED; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-1BETA; INTERLEUKIN-6; ISOXAZOLES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650224969     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70033-7     Document Type: Article

References (27)

1. Bartnicka L, Kurzawski M, Droździk A, Płońska-Gościniak E, Górnik W, Droździk M: Effect of ABCB1 (MDR1) 3435C >T and 2677G >A,T polymorphisms and P-glycoprotein inhibitors on salivary digoxin secretion in congestive heart failure patients. Pharmacol Rep, 2007, 59, 323-329.
2. Brazelton TR, Morris RE: Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol, 1996, 8, 710-720.
3. Burger D, Begué-Pastor N, Benavent S, Gruaz L, Kaufmann MT, Chicheportiche R, Dayer JM: The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Rheumatology, 2003, 42, 89-96.
4. Chrzanowska M, Kurzawski M, Droździk M, Mazik M, Oko A, Czekalski S: Thiopurine S-methyltransferase phenotype-genotype correlation in hemodialyzed patients. Pharmacol Rep, 2006, 58, 973-978.
5. Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA: The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry, 1996, 35, 1270-1273.
6. Elkayam O, Yaron I, Shirazi I, Judovitch R, Caspi D, Yaron M: Active leflunomide metabolite inhibits interleukin 1β, tumour necrosis factor α, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. Ann Rheum Dis, 2003, 62, 440-443.
7. Fairbanks LD, Jacomelli G, Micheli V, Slade T, Simmonds HA: Severe pyridine nucleotide depletion in fibroblasts from Lesch-Nyhan patients. Biochem J, 2002, 366, 265-272.
8. Felson DT, Anderson JJ, Boers M: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum, 1995, 38, 727-735.
9. Felson DT, Anderson JJ, Boers M: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum, 1993, 36, 729-740.
10. Herrmann ML, Schleyerbach R, Kirschbaum BJ: Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology, 2000, 47, 273-289.
11. Kotrych K, Sulikowski T, Domański L, Białecka M, Droździk M: Polymorphism in the P-glycoprotein drug transporter MDR1 gene in renal transplant patients treated with cyclosporin A in a Polish population. Pharmacol Rep, 2007, 59, 199-205.
12. Kurzawski M, Bartnicka L, Florczak M, Górnik W, Droździk M: Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients. Pharmacol Rep, 2007, 59, 107-11.
13. Kurzawski M, Pawlik A, Czerny B, Domanski L, Rozanski J, Drozdzik M: Frequencies of the common promoter polymorphisms in cytokine genes in a Polish population. Int J Immunogenet, 2005, 32, 285-291.
14. Kurzawski M, Pawlik A, Górnik W, Droździk M: Frequency of common MDR1 gene variants in a Polish population. Pharmacol Rep, 2006, 58, 35-40.
15. Li WD, Ran GX, Teng HL, Lin ZB: Dynamic effects of leflunomide on IL-1, IL-6, and TNF-alpha activity produced from peritoneal macrophages in adjuvant arthritis rats. Acta Pharmacol Sin, 2002, 23, 752-756.
16. Litinsky I, Paran D, Levartovsky D, Wigler I, Kaufman I, Yaron I, Yaron M et al.: The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. Cytokine, 2006, 33, 106-110.
17. Manna SK, Aggarwal BB: Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-κB activation and gene expression. J Immunol, 1999, 162, 2095-2102.
18. Martin K, Bentaberry F, Dumoulin C, Dehais J, Haramburu F, Bégaud B, Schaeverbeke T: Effectiveness and safety profile of leflunomide in rheumatoid arthritis: actual practice compared with clinical trials. Clin Exp Rheumatol, 2005, 23, 80-84.
19. Migita K, Miyashita T, Ishibashi H, Maeda Y, Nakamura M, Yatsuhashi H, Ida H et al.: Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1β stimulated rheumatoid synovial fibroblasts. Clin Exp Immunol, 2004, 137, 612-616.
20. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, Popovic M et al.: Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum, 1995, 38, 1595-1603.
21. Pawlik A, Kurzawski M, Górnik W, Dabrowska-Zamojcin E, Droździk M: 677C > T and 1298A > C MTHFR polymorphisms affect arechin treatment outcome in rheumatoid arthritis. Pharmacol Rep, 2007, 59, 721-726.
22. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP: Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum, 1983, 26, 1346-1353.
23. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999, 353, 259-266.
24. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R et al: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med, 1999, 159, 2542-2550.
25. Van Roon EN, Jansen TL, Mourad L, Houtman PM, Bruyn GA, Griep EN, Wilffert B et al.: Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. Br J Clin Pharmacol, 2004, 57, 790-797.
26. Vergne-Salle P, Léger DY, Bertin P, Trèves R, Beneytout JL, Liagre B: Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes. Cytokine, 2005, 31, 335-348.
27. Wolfe F, O'Dell JR, Kavanaugh A, Wilske K, Pincus T: Evaluating severity and status in rheumatoid arthritis. J Rheumatol, 2001, 28, 1453-1462.